Next Article in Journal
π-Donor/π-Acceptor Interactions for the Encapsulation of Neurotransmitters on Functionalized Polysilicon-Based Microparticles
Next Article in Special Issue
Hyaluronic Acid Nanoparticles as Nanomedicine for Treatment of Inflammatory Diseases
Previous Article in Journal
Schizonepeta Tenuifolia with Alpinia Oxyphylla Alleviates Atopic Dermatitis and Improves the Gut Microbiome in Nc/Nga Mice
Previous Article in Special Issue
Interaction of Lipoplex with Albumin Enhances Gene Expression in Hepatitis Mice
Open AccessArticle

Anti-Inflammatory Polymeric Nanoparticles Based on Ketoprofen and Dexamethasone

1
Biomaterials Group, Institute of Polymer Science and Technology (ICTP-CSIC), 28006 Madrid, Spain
2
Networking Biomedical Research Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28029 Madrid, Spain
3
Department of Immunology and Oncology, and NanoBiomedicine Initiative, Spanish National Center for Biotechnology (CNB-CSIC), 28049 Madrid, Spain
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(8), 723; https://doi.org/10.3390/pharmaceutics12080723
Received: 10 June 2020 / Revised: 28 July 2020 / Accepted: 29 July 2020 / Published: 31 July 2020
Polymeric nanoparticles that combine dexamethasone and naproxen reduce inflammation and synergistically inhibit Interleukin-12b (Il12b) transcription in macrophages. This effect can be the result of a cyclooxygenase-dependent or a cyclooxygenase-independent mechanism. The aim of this work is to obtain potent anti-inflammatory polymeric nanoparticles by the combination of dexamethasone and ketoprofen, one of the most efficient cyclooxygenase-inhibitors among non-steroidal anti-inflammatory drugs, with appropriate hydrodynamic properties to facilitate accumulation and co-release of drugs in inflamed tissue. Nanoparticles are spherical with hydrodynamic diameter (117 ± 1 nm), polydispersity (0.139 ± 0.004), and surface charge (+30 ± 1 mV), which confer them with high stability and facilitate both macrophage uptake and internalization pathways to favor their retention at the inflamed areas and lysosomal degradation and drug release, respectively. In vitro biological studies concluded that the dexamethasone-loaded ketoprofen-bearing system is non-cytotoxic and efficiently reduces lipopolysaccharide-induced nitric oxide release. The RT-qPCR analysis shows that the ketoprofen nanoparticles were able to reduce to almost basal levels the expression of tested pro-inflammatory markers and increase the gene expression of anti-inflammatory cytokines under inflammatory conditions. However, the synergistic inhibition of Il12b observed in nanoparticles that combine dexamethasone and naproxen was not observed in nanoparticles that combine dexamethasone and ketoprofen, suggesting that the synergistic trans-repression of Il12b observed in the first case was not mediated by cyclooxygenase-dependent pathways. View Full-Text
Keywords: nanoparticles; ketoprofen; dexamethasone; inflammation; macrophages; M1 and M2 markers; Il12-p40 subunit nanoparticles; ketoprofen; dexamethasone; inflammation; macrophages; M1 and M2 markers; Il12-p40 subunit
Show Figures

Graphical abstract

MDPI and ACS Style

Espinosa-Cano, E.; Aguilar, M.R.; Portilla, Y.; Barber, D.F.; San Román, J. Anti-Inflammatory Polymeric Nanoparticles Based on Ketoprofen and Dexamethasone. Pharmaceutics 2020, 12, 723.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop